MCID: HLC007
MIFTS: 57

Helicobacter Pylori Infection

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Helicobacter Pylori Infection

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection 57 71
Helicobacter Pylori Infection, Susceptibility to 57 28 5 38
H. Pylori Infection, Susceptibility to 57 12
Helicobacter Pylori Infections 41
H. Pylori Infection 57

Characteristics:


Inheritance:

Not determined 57

Classifications:



External Ids:

OMIM® 57 600263
MedGen 40 C1838332
UMLS 71 C0850666

Summaries for Helicobacter Pylori Infection

MedlinePlus: 41 Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40% of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you: Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to penicillin allergy and hepatitis b, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are 4-1BB Pathway and Interferon gamma signaling. The drugs Azithromycin and Roxithromycin have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and bone marrow, and related phenotypes are helicobacter pylori infection and renal/urinary system

OMIM®: 57 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263) (Updated 08-Dec-2022)

Related Diseases for Helicobacter Pylori Infection

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 717)
# Related Disease Score Top Affiliating Genes
1 penicillin allergy 30.2 IFNGR1 IFNG
2 hepatitis b 30.0 IFNGR1 IFNG
3 typhoid fever 30.0 IFNGR1 IFNG
4 behcet syndrome 29.9 IFNGR1 IFNG
5 salmonellosis 29.9 IFNGR1 IFNG
6 pulmonary tuberculosis 29.7 IFNGR1 IFNG
7 lung disease 29.1 IFNGR1 IFNG
8 gastric cancer 11.6
9 gastritis 11.6
10 peptic ulcer disease 11.5
11 duodenal ulcer 11.4
12 diffuse gastric and lobular breast cancer syndrome 11.3
13 atrophic gastritis 11.3
14 gastric ulcer 11.3
15 lymphoma, mucosa-associated lymphoid type 11.2
16 gastric adenocarcinoma 11.1
17 gastroesophageal reflux 11.1
18 gastrointestinal system disease 11.1
19 iron metabolism disease 11.1
20 deficiency anemia 11.1
21 esophagitis 11.0
22 purpura 11.0
23 iron deficiency anemia 11.0
24 thrombocytopenia due to platelet alloimmunization 11.0
25 common cold 11.0
26 adenocarcinoma 11.0
27 thrombocytopenic purpura, autoimmune 11.0
28 stomach disease 11.0
29 peptic esophagitis 11.0
30 gastric lymphoma 10.9
31 duodenitis 10.9
32 barrett esophagus 10.9
33 microinvasive gastric cancer 10.9
34 urticaria 10.9
35 non-alcoholic fatty liver disease 10.8
36 liver cirrhosis 10.8
37 esophagus adenocarcinoma 10.8
38 chronic urticaria 10.8
39 liver disease 10.8
40 fatty liver disease 10.8
41 diarrhea 10.8
42 celiac disease 1 10.8
43 coronary heart disease 1 10.8
44 type 2 diabetes mellitus 10.8
45 diabetes mellitus 10.8
46 hypoascorbemia 10.8
47 inflammatory bowel disease 10.8
48 lymphoma 10.8
49 b-cell lymphoma 10.8
50 heart disease 10.8

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:



Diseases related to Helicobacter Pylori Infection

Symptoms & Phenotypes for Helicobacter Pylori Infection

Human phenotypes related to Helicobacter Pylori Infection:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 helicobacter pylori infection 30 HP:0005202

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
G I:
helicobacter pylori infection susceptibility

Clinical features from OMIM®:

600263 (Updated 08-Dec-2022)

UMLS symptoms related to Helicobacter Pylori Infection:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.8 FUT4 IFNG IFNGR1

Drugs & Therapeutics for Helicobacter Pylori Infection

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 447043
2
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 6915744
3
Coal tar Approved Phase 4 8007-45-2
4
Loperamide Approved Phase 4 53179-11-6 3955
5
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521 16682734
6
Titanium dioxide Approved Phase 4 13463-67-7
7
Trimebutine Approved Phase 4 39133-31-8 5573
8
Rifabutin Approved, Investigational Phase 4 72559-06-9 46783538 6323490
9
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
10
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
11
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
12
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
13
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
14
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
15
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
16
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Ofloxacin Approved Phase 4 82419-36-1 4583
19
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
20
Ubidecarenone Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
21
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23
Sulforaphane Investigational Phase 4 4478-93-7, 142825-10-3 5350
24
Lactoferrin Investigational Phase 4 151186-19-5
25
Meclocycline Investigational Phase 4 2013-58-3 54684337
26 Fluoroquinolones Phase 4
27 Neurotransmitter Agents Phase 4
28 Antiviral Agents Phase 4
29 Antidotes Phase 4
30 Antioxidants Phase 4
31 Ubiquinone Phase 4
32 Bile Acids and Salts Phase 4
33 Antidiarrheals Phase 4
34 Parasympatholytics Phase 4
35 Antimalarials Phase 4
36 Penicillins Phase 4
37 Acidophilus Phase 4
38 Bifidobacterium Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Expectorants Phase 4
41 Respiratory System Agents Phase 4
42 Citrate Phase 4
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
44 Protective Agents Phase 4
45 Pharmaceutical Solutions Phase 4
46 Bee Products Phase 4
47 Propolis Phase 4
48 Amoxicillin-Potassium Clavulanate Combination Phase 4
49 beta-Lactamase Inhibitors Phase 4
50
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946

Interventional clinical trials:

(show top 50) (show all 382)
# Name Status NCT ID Phase Drugs
1 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
2 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Unknown status NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
3 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
4 Analysis of the Impact of Helicobacter Pylori Infection and Eradication on Salivary Microbiome in Adults by 16S Pyrosequencing Unknown status NCT03730766 Phase 4 Esomeprazole;Amoxicillin;Bismuth Potassium Citrate
5 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
6 Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial Unknown status NCT03208426 Phase 4 Esomeprazole (S14);Esomeprazole (BQ10);Amoxicillin (ST14);Clarithromycin (ST14);Metronidazole (ST14);dibismuth trioxide 120mg (BQ10);Metronidazole (BQ10);tetracycline (BQ10)
7 14-Day Antimicrobial Susceptibility Testing Guided Therapy Versus Personal Medication History Guided Therapy as a Rescue Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03565484 Phase 4 susceptibility guided therapy;personal medication history guided therapy;salvage treatment for failed eradication
8 Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01607918 Phase 4 D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
9 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03571230 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone);one proton pump inhibitor(PPI);Colloidal Bismuth Pectin;two antibiotics for failed eradication(tetracyclin,furazolidone)
10 Double-blind, Placebo-controlled, Randomized Study for Assesment of the Efficiency and Safety Quadruple Therapy for Helicobacter Pylori Infection With or Without the Addition of Saccharomyces Boulardi Probiotic Unknown status NCT03997279 Phase 4 Saccharomyces boulardii;Placebo
11 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
12 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
13 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
14 Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: an Open Randomized Pilot Study Unknown status NCT03658733 Phase 4 esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days);rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
15 Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: a Pilot Study Unknown status NCT03616405 Phase 4 rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
16 Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease Unknown status NCT04432233 Phase 4 Esomeprazole;Metronidazole;Levofloxacin
17 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT01537055 Phase 4 levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
18 Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Unknown status NCT02934048 Phase 4
19 Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection Unknown status NCT01725906 Phase 4 empirical therapy;Genotypic resistance guided therapy
20 Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy Unknown status NCT02894268 Phase 4 Doxycycline;Furazolidone;Esomeprazole;Colloidal Bismuth Subcitrate;Sensitivity antibiotics
21 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Unknown status NCT03299725 Phase 4 colloidal bismuth sub-citrate
22 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
23 A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis Unknown status NCT03908619 Phase 4 Omeprazole 20mg;Esomeprazole 20mg;Rabeprazole Sodium 20mg;Vonoprazan
24 Genotypic Resistance-guided Triple Therapy Versus Empirical Concomitant Therapy for First-line H. Pylori Eradication. Unknown status NCT04090021 Phase 4 Esomeprazole 40mg;Clarithromycin 500mg;Metronidazole 500 mg;Amoxicillin 1000 MG;Levofloxacin 500mg;Rifabutin 150 MG
25 Bismuth-Metronidazole Triple Versus Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Randomized Controlled Trial Unknown status NCT04667299 Phase 4 Rabeprazole;Bismuth potassium citrate;Metronidazole;Amoxicillin
26 Helicobacter Pylori Eradication According to DPO-PCR Methods: Duration of Triple Therapy and Bismuth Quadruple According to Clarithromycin Resistance Patterns Unknown status NCT04147065 Phase 4 Duration of eradication regimen
27 The Efficacy of Probiotic Supplementation in the Reduction of Adverse Effects and Dysbiosis of Helicobacter Pylori Eradication Therapy - A Double Blind, Multi-center Randomized, Placebo Controlled Trial Unknown status NCT03722433 Phase 4 Vigiis 101-LAB and sequential therapy;Placebo and sequential therapy
28 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
29 Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori: A Pilot Study Unknown status NCT03726099 Phase 4 esomeprazole, amoxicillin, furazolidone,tetracycline
30 The Effect of Broccoli Sprout Extract and Probiotics on Proton Pump Inhibitor-based Triple Therapy for Eradication of Helicobacter Pylori: a Prospective Randomized Trial Unknown status NCT03220542 Phase 4 Probiotics;Esomeprazole;Amoxicillin;Clarithromycin
31 Comparison of Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori- a Multicenter Randomized Trial Unknown status NCT03556254 Phase 4 GGT;SGT
32 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
33 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
34 Phase 4 Study of Helicobacter Pylori Eradication Therapy Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
35 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
36 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin
37 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
38 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
39 Comparison of Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial Unknown status NCT03555526 Phase 4 Esomeprazole 40mg;Amoxicillin;metronidazole;Levofloxacin 500mg;Clarithromycin ER;Dibismuth trioxide;tetracycline
40 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
41 Prospective Randomized Trial: Comparison Between Optimized-dose Amoxicillin and Standard-dose Amoxicillin for Quadruple Therapy in the Treatment of Helicobacter Pylori Infection in Tunisian Patients Completed NCT05635942 Phase 4 optimized quadruple therapy;standard quadruple therapy
42 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin
43 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
44 A Double Blind Randomized Study for Treatment of Helicobacter Pylori Infection: 14-day Non-bismuth Quadruple Therapy Versus Triple Therapy. Completed NCT04769583 Phase 4 metronidazole based quadriple therapy;placebo based quadriple therapy
45 Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Completed NCT02711176 Phase 4 Nexium;Tinafas;Tavanex;Lanzol;Klacid;Iramox
46 Randomized Clinical Trial: the Comparison of 15-day Sequential and 10-day Sequential Therapy to PPI-based Triple Therapy for Helicobacter Pylori Infection in Korea Completed NCT01887249 Phase 4 Clarithromycin;metronidazole;esomeprazole
47 Effect of Saccaromyces Boulardii CNCM I-745 Supplementation on the Fecal Resistome of Patients Treated Against Helicobacter Pylori Infection Completed NCT04786938 Phase 4 Saccharomyces Boulardii-Containing Product in Oral Dose Form
48 A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
49 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
50 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin

Search NIH Clinical Center for Helicobacter Pylori Infection

Genetic Tests for Helicobacter Pylori Infection

Genetic tests related to Helicobacter Pylori Infection:

# Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 28 IFNGR1

Anatomical Context for Helicobacter Pylori Infection

Organs/tissues related to Helicobacter Pylori Infection:

MalaCards : Kidney, Liver, Bone Marrow, Brain, T Cells, Whole Blood, Heart

Publications for Helicobacter Pylori Infection

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 20476)
# Title Authors PMID Year
1
Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. 62 57 5
12516030 2003
2
Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. 62 57
15310903 2004
3
Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. 62 57
12730721 2003
4
Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. 62 57
11535550 2001
5
Transmission of Helicobacter pylori infection. 62 57
7672655 1995
6
Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection. 62 57
7878011 1995
7
Helicobacter pylori infection: genetic and environmental influences. A study of twins. 62 57
8185146 1994
8
Seroprevalence of helicobacter pylori infection in couples. 62 57
2037687 1991
9
Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. 62 41
36376474 2022
10
Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. 62 41
36335970 2022
11
A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. 57
22387998 2012
12
A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. 5
19488747 2009
13
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 57
18488030 2008
14
Helicobacter exploits integrin for type IV secretion and kinase activation. 57
17943123 2007
15
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. 5
16690980 2006
16
Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. 57
15051885 2004
17
Treatment of Helicobacter gastritis with IL-4 requires somatostatin. 57
14555768 2003
18
Protective immunity against Helicobacter is characterized by a unique transcriptional signature. 57
14528007 2003
19
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. 57
12598897 2003
20
Helicobacter pylori and gastrointestinal tract adenocarcinomas. 57
11902583 2002
21
The complete genome sequence of the gastric pathogen Helicobacter pylori. 57
9252185 1997
22
Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. 57
8040281 1994
23
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. 57
8163943 1994
24
Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. 57
8018146 1993
25
Purification and characterization of the vacuolating toxin from Helicobacter pylori. 57
1587837 1992
26
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. 57
6134060 1983
27
Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial. 41
36426355 2022
28
Trace element levels in serum and gastric mucosa in patients with Helicobacter pylori positive and negative gastritis. 62
36435152 2023
29
Methods to Evaluate the Effects of HAT/KAT Inhibition on SIAH2-Driven Reactive Oxygen Species Generation in Helicobacter pylori-Infected Gastric Epithelial Cells. 62
36255634 2023
30
Mass screening and eradication of Helicobacter pylori as the policy recommendations for gastric cancer prevention. 62
36085264 2022
31
Inhibition of MDFI attenuates proliferation and glycolysis of Helicobacter pylori-infected gastric cancer cells by inhibiting Wnt/β-catenin pathway. 62
36116024 2022
32
P16 gene promoter methylation is associated with oncogenesis and progression of gastric carcinomas: A systematic review and meta-analysis. 62
36270449 2022
33
Cokeromyces recurvatus Incidentally Found in a Patient with Gastric Outlet Obstruction. 62
35945314 2022
34
Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis. 62
36458328 2022
35
Magnetic controlled capsule endoscope (MCCE)'s diagnostic performance for H. pylori infection status based on the Kyoto classification of gastritis. 62
36474169 2022
36
The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas. 62
35098820 2022
37
Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin-resistant using intragastric fluid. 62
36263754 2022
38
Human gastric fibroblasts ameliorate A20-dependent cell survival in co-cultured gastric epithelial cells infected by Helicobacter pylori. 62
36162648 2022
39
Perspectives from recent advances of Helicobacter pylori vaccines research. 62
36134470 2022
40
Relation of CRP gene variants to altered risk of Helicobacter pylori - associated chronic gastritis: A case-control study in Tunisia. 62
36162594 2022
41
Insulin-like growth factor 1 serum levels in different stages of gastric cancer and their association with Helicobacter pylori status. 62
36240982 2022
42
Prevalence and factors associated with atrophic gastritis and intestinal metaplasia: A multivariate, hospital-based, statistical analysis. 62
36470067 2022
43
Helicobacter pyhlori regulated microRNA map of human gastric cells. 62
36468839 2022
44
Potential Non-invasive Biomarkers of Helicobacter pylori-Associated Gastric Cancer. 62
34767179 2022
45
Overview of epidemiological characteristics, clinical features, and risk factors of gastric cancer in Asia-Pacific region. 62
35073453 2022
46
Effect of Helicobacter pylori infection and its eradication on the expression of tight junction proteins in the gastric epithelium in relation to gastric carcinogenesis. 62
36063450 2022
47
Helicobacter pylori infection: is there circulating vacuolating cytotoxin A or cytotoxin-associated gene A protein? 62
36463198 2022
48
[The correlation between reflux esophagitis and Helicobacter pylori infection based on natural population]. 62
36456513 2022
49
Helicobacter pylori infection and risk of multiple sclerosis: An updated meta-analysis. 62
36046943 2022
50
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial. 62
36458325 2022

Variations for Helicobacter Pylori Infection

ClinVar genetic disease variations for Helicobacter Pylori Infection:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IFNGR1 NM_000416.3(IFNGR1):c.-56T>C SNV Risk Factor
355565 rs2234711 GRCh37: 6:137540520-137540520
GRCh38: 6:137219383-137219383
2 IFNGR1 NM_000416.3(IFNGR1):c.974C>T (p.Pro325Leu) SNV Uncertain Significance
992563 rs753495798 GRCh37: 6:137519664-137519664
GRCh38: 6:137198527-137198527

Expression for Helicobacter Pylori Infection

LifeMap Discovery
Genes differentially expressed in tissues of Helicobacter Pylori Infection patients vs. healthy controls: 35 (show top 50) (show all 94)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FDCSP follicular dendritic cell secreted protein Gastrointestinal Tract,Stomach + 9.19 0.000
2 DMBT1 deleted in malignant brain tumors 1 Gastrointestinal Tract,Stomach + 7.69 0.000
3 REG3G regenerating family member 3 gamma Gastrointestinal Tract,Stomach + 6.56 0.000
4 CR2 complement C3d receptor 2 Gastrointestinal Tract,Stomach + 6.52 0.000
5 OLFM4 olfactomedin 4 Gastrointestinal Tract,Stomach + 6.34 0.001
6 CXCL13 C-X-C motif chemokine ligand 13 Gastrointestinal Tract,Stomach + 6.24 0.000
7 REG3A regenerating family member 3 alpha Gastrointestinal Tract,Stomach + 6.15 0.000
8 CD19 CD19 molecule Gastrointestinal Tract,Stomach + 5.25 0.000
9 FCRL3 Fc receptor like 3 Gastrointestinal Tract,Stomach + 5.18 0.000
10 CXCR5 C-X-C motif chemokine receptor 5 Gastrointestinal Tract,Stomach + 5.12 0.000
11 SAA2 serum amyloid A2 Gastrointestinal Tract,Stomach + 4.81 0.000
12 MS4A1 membrane spanning 4-domains A1 Gastrointestinal Tract,Stomach + 4.76 0.000
13 CCL20 C-C motif chemokine ligand 20 Gastrointestinal Tract,Stomach + 4.64 0.000
14 ABCA12 ATP binding cassette subfamily A member 12 Gastrointestinal Tract,Stomach + 4.60 0.000
15 SAA1 serum amyloid A1 Gastrointestinal Tract,Stomach + 4.59 0.000
16 NLRP7 NLR family pyrin domain containing 7 Gastrointestinal Tract,Stomach + 4.56 0.000
17 CCL19 C-C motif chemokine ligand 19 Gastrointestinal Tract,Stomach + 4.52 0.000
18 VNN1 vanin 1 Gastrointestinal Tract,Stomach + 4.51 0.000
19 BPIFB1 BPI fold containing family B member 1 Gastrointestinal Tract,Stomach + 4.48 0.000
20 AFAP1-AS1 AFAP1 antisense RNA 1 Gastrointestinal Tract,Stomach + 4.47 0.000
21 CCR7 C-C motif chemokine receptor 7 Gastrointestinal Tract,Stomach + 4.38 0.000
22 CXCL1 C-X-C motif chemokine ligand 1 Gastrointestinal Tract,Stomach + 4.33 0.000
23 CHI3L1 chitinase 3 like 1 Gastrointestinal Tract,Stomach + 4.30 0.000
24 DEFB4A defensin beta 4A Gastrointestinal Tract,Stomach + 4.25 0.000
25 LAIR2 leukocyte associated immunoglobulin like receptor 2 Gastrointestinal Tract,Stomach + 4.22 0.000
26 TCL1A TCL1 family AKT coactivator A Gastrointestinal Tract,Stomach + 4.16 0.000
27 SELL selectin L Gastrointestinal Tract,Stomach + 4.14 0.000
28 S100A8 S100 calcium binding protein A8 Gastrointestinal Tract,Stomach + 4.09 0.000
29 FCRL5 Fc receptor like 5 Gastrointestinal Tract,Stomach + 3.95 0.000
30 TLR10 toll like receptor 10 Gastrointestinal Tract,Stomach + 3.95 0.000
31 C3 complement C3 Gastrointestinal Tract,Stomach + 3.95 0.000
32 LCN2 lipocalin 2 Gastrointestinal Tract,Stomach + 3.92 0.000
33 MMP7 matrix metallopeptidase 7 Gastrointestinal Tract,Stomach + 3.88 0.000
34 CD28 CD28 molecule Gastrointestinal Tract,Stomach + 3.80 0.000
35 BLK BLK proto-oncogene, Src family tyrosine kinase Gastrointestinal Tract,Stomach + 3.80 0.000
36 CD22 CD22 molecule Gastrointestinal Tract,Stomach + 3.80 0.000
37 FCRL2 Fc receptor like 2 Gastrointestinal Tract,Stomach + 3.78 0.000
38 CXCL8 C-X-C motif chemokine ligand 8 Gastrointestinal Tract,Stomach + 3.77 0.000
39 FCRL4 Fc receptor like 4 Gastrointestinal Tract,Stomach + 3.72 0.000
40 CXCL2 C-X-C motif chemokine ligand 2 Gastrointestinal Tract,Stomach + 3.69 0.000
41 CD180 CD180 molecule Gastrointestinal Tract,Stomach + 3.68 0.000
42 PLA2G7 phospholipase A2 group VII Gastrointestinal Tract,Stomach + 3.66 0.000
43 FCAMR Fc alpha and mu receptor Gastrointestinal Tract,Stomach + 3.65 0.000
44 AQP9 aquaporin 9 Gastrointestinal Tract,Stomach + 3.64 0.000
45 FCRLA Fc receptor like A Gastrointestinal Tract,Stomach + 3.63 0.000
46 AIM2 absent in melanoma 2 Gastrointestinal Tract,Stomach + 3.63 0.000
47 LTF lactotransferrin Gastrointestinal Tract,Stomach + 3.63 0.000
48 KRT6B keratin 6B Gastrointestinal Tract,Stomach + 3.60 0.000
49 C6 complement C6 Gastrointestinal Tract,Stomach - 3.60 0.000
50 NEURL3 neuralized E3 ubiquitin protein ligase 3 Gastrointestinal Tract,Stomach + 3.59 0.000
Search GEO for disease gene expression data for Helicobacter Pylori Infection.

Pathways for Helicobacter Pylori Infection

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.16 IFNGR1 IFNG
2
Show member pathways
12.03 IFNGR1 IFNG
3
Show member pathways
11.92 IFNGR1 IFNG
4
Show member pathways
11.83 IFNGR1 IFNG
5 11.73 IFNGR1 IFNG
6 11.64 IFNGR1 IFNG
7
Show member pathways
11.46 IFNGR1 IFNG
8 11.39 IFNGR1 IFNG
9
Show member pathways
11.31 IFNGR1 IFNG
10 11.21 IFNGR1 IFNG
11
Show member pathways
11.09 IFNGR1 IFNG
12 11.08 IFNGR1 IFNG
13 10.99 IFNGR1 IFNG
14 10.86 IFNGR1 IFNG
15 10.52 IFNGR1 IFNG
16 10.11 IFNGR1 IFNG

GO Terms for Helicobacter Pylori Infection

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to virus GO:0009615 9.73 IFNGR1 IFNG
2 positive regulation of tumor necrosis factor production GO:0032760 9.71 IFNGR1 IFNG
3 cellular response to virus GO:0098586 9.67 IFNGR1 IFNG
4 microglial cell activation GO:0001774 9.62 IFNGR1 IFNG
5 positive regulation of amyloid-beta formation GO:1902004 9.56 IFNGR1 IFNG
6 astrocyte activation GO:0048143 9.46 IFNGR1 IFNG
7 type II interferon-mediated signaling pathway GO:0060333 9.26 IFNGR1 IFNG
8 negative regulation of amyloid-beta clearance GO:1900222 8.92 IFNGR1 IFNG

Sources for Helicobacter Pylori Infection

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....